Novartis : Six-Year Study Reveals Benefits Of Kesimpta In Newly Diagnosed Relapsing MS Patients
17/4 07:48
(RTTNews) - Novartis AG (NVS) said that an analysis of treatment-naive people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six years provided long-term benefits, including fewer relapses, profoundly suppressed MRI l...